Samrat Pharmachem Reports Strong Financial Performance in Q1 FY25

Samrat Pharmachem, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending March 2024. The company’s stock has been given a ‘Hold’ call by MarketsMOJO.

According to the financial report, Samrat Pharmachem has shown a very positive performance in the quarter, with a score of 21 compared to 10 in the previous quarter. This is a significant improvement and reflects the company’s strong financial standing.

One of the key factors contributing to this positive performance is the growth in Profit Before Tax less Other Income (PBT) for the quarter. At Rs 2.23 crore, it has increased by 682.5% compared to the average PBT of the previous four quarters, which was Rs 0.29 crore. This indicates a very positive trend in the near term for PBT.

The company has also shown growth in its net sales for the half-yearly period, with a 29.09% increase year on year. This is a positive sign for the company’s sales trend in the near term.

In terms of operating profit, Samrat Pharmachem has recorded its highest PBDIT (Profit Before Depreciation, Interest, and Taxes) in the last five quarters at Rs 2.58 crore. This shows a positive trend in the company’s operating profit in the near term.

The operating profit margin for the quarter has also improved, reaching its highest at 3.19% in the last five quarters. This indicates an increase in the company’s efficiency.

Overall, Samrat Pharmachem has shown a positive trend in its financial performance for the quarter ending March 2024. With the highest PBT, PAT (Profit After Tax), and EPS (Earnings per Share) in the last five quarters, the company has demonstrated its ability to generate higher earnings for its shareholders.